We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Can DENTSPLY Sirona (XRAY) Deliver a Beat in Q2 Earnings?
Read MoreHide Full Article
York, PA-based DENTSPLY Sirona Inc. (XRAY - Free Report) , a dental solutions company, is expected to report second-quarter 2017 results on Aug 9.
DENTSPLY Sirona’s track record has been quite impressive, with the company beating estimates in three of the trailing four quarters. Last quarter, it delivered a negative earnings surprise of 3.92%, taking the four-quarter average to a positive 3.12%. Let’s see how things are shaping up prior to this quarter.
Why a Likely Positive Surprise?
Our proven model shows that DENTSPLY is likely to beat on earnings because it has the right combination of the two key components.
Zacks ESP: DENTSPLY currently has an Earnings ESP of +4.55%. This is because the Most Accurate estimate is 69 cents, while the Zacks Consensus Estimate comes is pegged at 66 cents. A favorable Earnings ESP serves as a meaningful and leading indicator of a likely positive earnings surprise. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: DENTSPLY currently carries a Zacks Rank #3 (Hold). It should be noted that stocks with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 have a significantly higher chance of beating earnings. Conversely, stocks with a Zacks Rank #4 or 5 (Sell rated) should never be considered going into an earnings announcement.
The combination of DENTSPLY’s Zacks Rank #3 and a positive ESP make us reasonably confident of an earnings beat.
DENTSPLY’s dental & healthcare consumables segment holds considerable promise. Notably, this segment provides a broad spectrum of products that include preventive, restorative, instruments, endodontic and laboratory dental products, as well as consumable medical device products.
Furthermore, DENTSPLY’s dental implants, CAD/CAM systems, imaging systems, treatment centers and orthodontic products in the technology segment are likely to drive sales.
We are also upbeat about the gradual recovery in the U.S. market. The emerging markets provide significant opportunities for the company as these areas are vastly untapped with low dental products’ penetration. For 2017, the company anticipates adjusted EPS in the range of $2.80–$2.90.
Stocks that Warrant a Look
Here are some other companies you may want to consider as our model shows that these also have the right combination of elements to post an earnings beat:
Genomic Health Inc. has an Earnings ESP of +16.67% and carries a Zacks Rank #3.
Pfizer Inc. (PFE - Free Report) has an Earnings ESP of +1.54% and carries a Zacks Rank #3.
More Stock News: Tech Opportunity Worth $386 Billion in 2017
From driverless cars to artificial intelligence, we've seen an unsurpassed growth of high-tech products in recent months. Yesterday's science-fiction is becoming today's reality. Despite all the innovation, there is a single component no tech company can survive without. Demand for this critical device will reach $387 billion this year alone, and it's likely to grow even faster in the future.
Zacks has released a brand-new Special Report to help you take advantage of this exciting investment opportunity. Most importantly, it reveals 4 stocks with massive profit potential. See these stocks now>>
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
Can DENTSPLY Sirona (XRAY) Deliver a Beat in Q2 Earnings?
York, PA-based DENTSPLY Sirona Inc. (XRAY - Free Report) , a dental solutions company, is expected to report second-quarter 2017 results on Aug 9.
DENTSPLY Sirona’s track record has been quite impressive, with the company beating estimates in three of the trailing four quarters. Last quarter, it delivered a negative earnings surprise of 3.92%, taking the four-quarter average to a positive 3.12%. Let’s see how things are shaping up prior to this quarter.
Why a Likely Positive Surprise?
Our proven model shows that DENTSPLY is likely to beat on earnings because it has the right combination of the two key components.
Zacks ESP: DENTSPLY currently has an Earnings ESP of +4.55%. This is because the Most Accurate estimate is 69 cents, while the Zacks Consensus Estimate comes is pegged at 66 cents. A favorable Earnings ESP serves as a meaningful and leading indicator of a likely positive earnings surprise. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: DENTSPLY currently carries a Zacks Rank #3 (Hold). It should be noted that stocks with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 have a significantly higher chance of beating earnings. Conversely, stocks with a Zacks Rank #4 or 5 (Sell rated) should never be considered going into an earnings announcement.
The combination of DENTSPLY’s Zacks Rank #3 and a positive ESP make us reasonably confident of an earnings beat.
DENTSPLY SIRONA Inc. Price and EPS Surprise
DENTSPLY SIRONA Inc. Price and EPS Surprise | DENTSPLY SIRONA Inc. Quote
Factors at Play
DENTSPLY’s dental & healthcare consumables segment holds considerable promise. Notably, this segment provides a broad spectrum of products that include preventive, restorative, instruments, endodontic and laboratory dental products, as well as consumable medical device products.
Furthermore, DENTSPLY’s dental implants, CAD/CAM systems, imaging systems, treatment centers and orthodontic products in the technology segment are likely to drive sales.
We are also upbeat about the gradual recovery in the U.S. market. The emerging markets provide significant opportunities for the company as these areas are vastly untapped with low dental products’ penetration. For 2017, the company anticipates adjusted EPS in the range of $2.80–$2.90.
Stocks that Warrant a Look
Here are some other companies you may want to consider as our model shows that these also have the right combination of elements to post an earnings beat:
Halyard Health, Inc. has an Earnings ESP of +5.26% and carries a Zacks Rank #2. You can see the complete list of today’s Zacks #1 Rank stocks here.
Genomic Health Inc. has an Earnings ESP of +16.67% and carries a Zacks Rank #3.
Pfizer Inc. (PFE - Free Report) has an Earnings ESP of +1.54% and carries a Zacks Rank #3.
More Stock News: Tech Opportunity Worth $386 Billion in 2017
From driverless cars to artificial intelligence, we've seen an unsurpassed growth of high-tech products in recent months. Yesterday's science-fiction is becoming today's reality. Despite all the innovation, there is a single component no tech company can survive without. Demand for this critical device will reach $387 billion this year alone, and it's likely to grow even faster in the future.
Zacks has released a brand-new Special Report to help you take advantage of this exciting investment opportunity. Most importantly, it reveals 4 stocks with massive profit potential. See these stocks now>>